Voronoi, Inc. · KRX:310210
Voronoi — Non-Deal Roadshow (July 2026)
51 slides from Voronoi's roadshow presentation, Jul 10, 2026
Slide 1: IR Book
Creating Novel Therapeutics For patients with Excellent Experts In Drug Design IR BOOK July 2026
Slide 2: Disclaimer
Investor Relations 2026 Disclaimer The purpose of this document is to explain the research activities, management planning, and other matters of and pertaining to Voronoi, its affiliates, and related companies (hereinafter collectively referred to as the “Company”), to shareholders, investors, and a
Slide 3: Voronoi Pipeline
Investor Relations 2026 VORONOI. Pipeline Clinical Phase Drug Company Indication Target Pre-clinical Phase 1/2 Pivotal/Phase 3 1L, EGFR common mutation (treatment-naïve) 1L ,EGFR uncommon mutation (treatment-naïve) Non-small cell lung cancer VRN11 (NSCLC) 2L EGFR-mutant with unknown resistance mecha
Slide 4: Content
Creating Novel Therapeutics For patients with Excellent Experts In Drug Design CONTENT 1. VRN11. EGFR NSCLC Targeted Therapy 2. VRN10. HER2-altered Solid Tumors Targeted Therapy
Slide 5: VRN11: EGFR NSCLC Targeted Therapy
Creating Novel Therapeutics For patients with Excellent Experts In Drug Design VRN11 EGFR NSCLC Targeted Therapy
Slide 6: EGFR Non-small cell lung cancer (NSCLC) Landscape
Investor Relations 2026 EGFR Non-small cell lung cancer(NSCLC) Landscape Phase 1a study ongoing in patients with EGFR-mutated NSCLC refractory to standard therapies, including EGFR TKIs Based on phase1a data, phase1b/2 study ongoing in EGFR treatment-naïve patients for first-line treatment [EGFR NSC
Slide 7: Clinical Update on VRN11: Game Changer in EGFR-Mutant NSCLC
Investor Relations 2026 Clinical Update on VRN11: Game Changer in EGFR-Mutant NSCLC Anticipated Addressing of Broad EGFR-Mutant Lung Cancer Unmet Needs, Driven by Meaningful Phase 1 Efficacy, Safety, and BBB Penetration Data “VRN11 demonstrates potential as a best-in-class 4th generation EGFR TKI.”
Slide 8: VRN11: Superior brain permeability, Better intracranial PFS
VRN11 Superior brain permeability, Better intracranial PFS
Slide 9: VRN11 vs Osimertinib: PFS/iPFS in brain metastasis patients
Investor Relations 2026 VRN11 ⇔ Osimertinib Comparison: Improvement in PFS/iPFS for brain metastasis patients Meaningful PFS/iPFSbenefit confirmed in patients with no treatment options post-3rd generation EGFR TKI Demonstrated clinical advantage: median intracranial PFS ≥ 9 months (N.R.) vs. Osimert
Slide 10: Robust progression inhibition of CNS metastases
Investor Relations 2026 Robust progression inhibition of CNS metastases Effective CNS progression inhibition at ≥160mg, overcoming high CNS metastasis rates of current EGFR TKIs Efficacy evaluable patients 160 mg 240 mg 320 mg 400 mg 480 mg Total All evaluable patients, N 12 14 6 5 2 39 CNS progress
Slide 11: VRN11 vs Osimertinib: in vivo BM/LM models
Investor Relations 2026 VRN11 ⇔ Osimertinib Comparison: in vivo BM/LM models Superior CNS tumor inhibition vs. Osimertinib in BM and LM in vivo models Intracranial (BM or LM) CDX model Luciferase signal in LM model Osimertinib VRN11 Vehicle (10 mg/kg QD) (10 mg/kg QD) Day 0 * Day 14 Day 32 *Euthanas
Slide 12: VRN11 vs Osimertinib: Brain Permeability & Target Engagement
Investor Relations 2026 VRN11 ⇔ Osimertinib Comparison: Brain Permeability & Target Engagement First-in-Class Human PoC data demonstrating 200% BBB penetration vs. Osimertinib (20%) Superior target engagement to Osimertinib: 4-fold higher in lung, 40-fold higher in brain Free Drug Concentration in C
Slide 13: Case Report: Clinical efficacy in brain metastasis patients (1)
Investor Relations 2026 Case Report: Clinical efficacy in brain metastasis patients(1) Antitumor activity confirmed from 40mg in phase 1 trial for brain metastases Baseline C2D1 Phase 1a. Dose escalation Brain 1, 2 lesion 480mg 240mg ✓ Decreasein size of CNS lesion 400mg 320mg Baseline C2D1 240mg Br
Slide 14: Case Report: Clinical efficacy in brain metastasis patients (2)
Investor Relations 2026 Case Report: Clinical efficacy in brain metastasis patients(2) Disappearance of brain lesions at first tumor assessment Post-VRN11 in 3rd-Gen EGFR TKI-pretreated patients Achieved overall PR (Partial Response) with 50% reduction in lung lesions 320mg: 47-yr female with EGFR D
Slide 15: Case Report: Clinical efficacy in brain metastasis patients (3)
Investor Relations 2026 Case Report: Clinical efficacy in brain metastasis patients(3) Disappearance of brain lesions at first tumor assessment Post-VRN11 in 3rd-Gen EGFR TKI-pretreated patients Achieved overall PR (Partial Response) with 38% reduction in lung lesions 400mg: 71-yr male with EGFR L85
Slide 16: VRN11: EGFR 2nd Line treatment
VRN11 EGFR 2nd Line treatment
Slide 17: VRN11 vs Osimertinib: PFS; 2L treatment
Investor Relations 2026 VRN11 ⇔ Osimertinib Comparison : Progression-free survival(PFS); 2L treatment VRN11, mPFSof ≥ 7 months in chemotherapy-pretreated patients Significant survival benefit over Osimertinib (4.07 months) in heavily pre-treated patients C797S VRN11: Progression-Free Survival (PFS)
Slide 18: Unmet needs in resistant/refractory patients
Investor Relations 2026 Unmet needs in resistant/refractory patients Current therapies show limited efficacy and safety in SOC–resistant/refractory patients Strong disease control observed in heavily pretreated patients supports the second-line exploration Key updates on VRN11(ph1a) SOC resistant/re
Slide 19: Case Report: Durable tumor suppression following standard therapy failure
Investor Relations 2026 Case Report: Demonstrated durable tumor suppression following standard therapy failure Confirmed sustained tumor reduction with VRN11 in an EGFR-mutant patient with 10 prior lines of therapy Representative Case in heavily-treated patient(240mg, EGFR L858R) Osimertinib + Pemet
Slide 20: VRN11: EGFR C797S
VRN11 EGFR C797S
Slide 21: Efficacy in Patients with EGFR C797S Mutation
Investor Relations 2026 Efficacy in Patients with EGFR C797S Mutation An objective response rate of 100% (6/6, partial responses)was observed in all patients with the EGFR C797S mutation treated at or above the efficacy dose (≥160 mg) Efficacy in Patients with EGFR C797S Mutation Representative Case
Slide 22: VRN11 vs Osimertinib: Comparative Clinical Profile
Investor Relations 2026 VRN11 ⇔ Osimertinib Comparison: Comparative Clinical Profile Indirect Comparison of 4th generation potency vs. 3rd generation standard of care Indirect Comparison of VRN11 vs. Osimertinib 20 Best change from baseline 40mg in target lesions, % 0 80mg 160mg -20 240mg 320mg -40
Slide 23: VRN11: The higher selectivity, The better safety
VRN11 The higher selectivity, The better safety
Slide 24: Favorable safety and tolerability profile in EGFR-mutant NSCLC patients
Investor Relations 2026 Favorable safety and tolerability profile in EGFR-mutant NSCLC patients Excellent tolerability confirmed with only a single case (≥Grade 3) of TRAE (1.5%) No major off-target toxicities reported, particularly irreversible or unpredictable adverse events VRN11 Osimertinib Comp
Slide 25: VRN11: Clinical Development Strategy
VRN11 Clinical Development Strategy
Slide 26: VRN11 Clinical development strategy
Investor Relations 2026 VRN11 Clinical development strategy Aims to address unmet needs across EGFR-mutant NSCLC, supported by strong efficacy, safety, and brain penetration data Brain Metastasis 2L post-3rd gen EGFR TKI (unknown) C797S • Superior Clinical data demonstrated to Osimertinib*: Kp,uu,CS
Slide 27: Phase 1/2 Clinical Trial Design
Investor Relations 2026 Phase 1/2 Clinical Trial Design Ongoing global phase 1 trial in South Korea, Taiwan, and Other regions 1H 2026, Phase 1b/2 IND approval and study initiation across select countries/sites Phase 1/2 Clinical Trial Design Phase1a Phase 1b/2 Phase 1b/2. Cohort Design (Dose escala
Slide 28: VRN11: EGFR 1st line treatment (CNS metastases)
VRN11 EGFR 1st line treatment (CNS metastases)
Slide 29: Targeted Therapies for NSCLC by Generation and BBB Penetration Rates
Investor Relations 2026 Targeted Therapies for NSCLC by Generation and BBB Penetration Rates (EGFR/ALK) Targeted Therapies for NSCLC by Generation and BBB Penetration Rates (EGFR/ALK) 1,2,3,4 EGFR TKI • Key Differentiations 1st Gen. Drug 3rd Gen. Drug Next Gen. Drug - Overcoming post-3rd Gen EGFR TK
Slide 30: Clinical Benchmark: Lorlatinib (ALK) historical efficacy data
Investor Relations 2026 Clinical Benchmark: Analysis of Lorlatinib(ALK) historical Efficacy data [ALK] Efficacy Comparison: Patients with CNS metastases at baseline PFS Comparison: Patients with CNS metastases at baseline Drug Lorlatinib1 Lorlatinib2,3 100 (Clinical study) (2L+, NCT01970865 ) (1L, C
Slide 31: Clinical Benchmark: Osimertinib (EGFR) historical efficacy data
Investor Relations 2026 Clinical Benchmark: Analysis of Osimertinib(EGFR) historical Efficacy data Unmet medical need for treatment options for CNS metastases in EGFR-mutant NSCLC [EGFR] Efficacy Comparison: Patients with CNS metastases at baseline PFS Comparison: Patients with CNS metastases at bas
Slide 32: VRN11: EGFR 1st line treatment
VRN11 EGFR 1st line treatment
Slide 33: PFS & Depth of Response Correlation (ALK, EGFR)
Investor Relations 2026 PFS & Depth of Response Correlation (ALK, EGFR) Correlation confirmed in ALK setting: Higher target engagement driving greater tumor reduction and extended PFS ALK inhibitor EGFR inhibitors 100 100 NVL-655 80 Lorlatinib(3rd gen) 80 R2 = 0.94 R2 = 0.88 VRN11 mPFS (m) PFS(m) 60
Slide 34: Preclinical and clinical evidence of efficacy in EGFR-mutant NSCLC
Investor Relations 2026 Preclinical and clinical evidence of efficacy in EGFR-mutant NSCLC Confirmed robust activity of VRN11 320mg across broad EGFR mutations 4-fold stronger target engagement vs. Osimertinib 80mg in EGFR del19/L858R, demonstrating distinct CNS superiority via exceptional BBB penet
Slide 35: In Vivo model-proven prediction of tumor response to VRN11
Investor Relations 2026 In Vivo model-proven prediction of tumor response to VRN11: Deeper Response VRN11 exhibits longer duration of response compared to osimertinib in subcutaneous CDX model Subcutaneous CDX model(PC9_Del19) Luciferase signal in SC model PC-9 Luc Vehicle Osimertinib VRN11 (10 mg/k
Slide 36: PFS & Depth of response correlation
Investor Relations 2026 PFS & Depth of response correlation Lower residual tumor cell count reducing risk of resistance/bypass pathways, leading to anticipated PFS prolongation Depth of Response: remaining cells ↓ → chance of resistance ↓1,2 Osimertinib Osimertinib mPFS Osimertinib (80mg) 18.9 month
Slide 37: PFS & Depth of response correlation
Investor Relations 2026 PFS & Depth of response correlation Less remaining tumor cells →less chance of resistance / bypass →longer duration of response / PFS VRN11 in 1L setting is expected with greater depth of response compared to existing EGFR TKIs Depth of Response: short term readout / EGFR NSC
Slide 38: Valuation
Valuation
Slide 39: VRN11: Pipeline valuation
Investor Relations 2026 VRN11: Pipeline valuation VRN11’s near-term potential as a second-line therapy alone is estimated to drive a corporate valuation of approximately USD 10B USD Bn Total 40 “an uplift in pipeline valuation” Pipeline value (estimated) 35 30 ✓ Initiate phase 1b/2 trial in treatmen
Slide 40: VRN11: Pipeline Valuation
Investor Relations 2026 VRN11: Pipeline Valuation Key assumptions (Unit: USD mn) Incidence among NSCLC Market share (EGFR TKIs) VRN11(2L; C797S) 10% increasing gradually* ■ Key Pipeline VRN11(BM) 30% increasing gradually* Probability of Category rNPV VRN11(2L; Unknown) 50% 58% Success VRN11(1L) 90%
Slide 41: PEER Valuation
Investor Relations 2026 PEER Valuation Market Cap USD 9.8B USD 2.6B (Jun 30, 2026) Addressable ALK EGFR Market (3~5% of NSCLC) (30~40% of NSCLC) Relative Value Assessment • Nuvalent’s ALK-targeted therapy NVL-655: Based on phase 1/2 data, currently valued at $9.8B in the U.S. (as of Jun 30, 2026) •
Slide 42: VRN10: HER2-altered Solid Tumors Targeted Therapy
Creating Novel Therapeutics For patients with Excellent Experts In Drug Design VRN10 HER2-altered Solid Tumors Targeted Therapy
Slide 43: Efficacy (1): HER2 mutant solid tumors
Investor Relations 2026 Efficacy(1): HER2 mutant solid tumors Antitumor activity confirmed in heavily pretreated HER2-mutant solid tumor patients treated with VRN10 Best Response in Target Lesion Size in target lesion, % 20 80mg SD SD PR PR PR Best change 0 160mg PD SD 240mg 320mg -20 ORR 43% (3/7)
Slide 44: Case report: HER2 S310Y lung adenocarcinoma
Investor Relations 2026 Case report: 160 mg, HER2 S310Y lung adenocarcinoma Durable partial response ongoing at 9+ months, with complete resolution of lung and breast lesions even after three prior regimens including chemotherapy Patient 004-003(HER2 S310Y): 56-yr female following progression on T-D
Slide 45: Efficacy (2): HER2-positive metastatic Breast Cancer
Investor Relations 2026 Efficacy(2): HER2-positive metastatic Breast Cancer 83% Disease control rate (DCR) confirmed in T-DXd-pretreated, HER2-positive breast cancer patients Best Response in Target Lesion Size in target lesion, % 20 SD SD SD Best change PR 0 160mg PD SD 240mg -20 ORR 17% (1/6) DCR
Slide 46: Case report: HER2 positive Breast cancer
Investor Relations 2026 Case report: 160 mg, HER2 positive Breast cancer Stabilized disease despite progression on numerous previous treatments including radiation and systemic HER2 targeted therapy Patient 005-002: 37-yr female patient with HER2-positive breast cancer (resected) and CNS metastases
Slide 47: Tumor responses observed in HER2-positive and HER2-mutant patients
Investor Relations 2026 Tumor responses observed in HER2-positive and HER2-mutant patients Antitumor activity confirmed in patients with HER2 overexpression and mutations in the Phase 1a study Integrated PK-PD-Tumor Response Analysis Tumor response(ex-vivo correlation) Patient HER2 status HER2 IHC 1
Slide 48: Efficacy (3): Brain penetration
Investor Relations 2026 Efficacy(3): Brain penetration Potential to address unmet medical needs for brain metastasis patients VRN10: Addressing unmet needs in brain mets Intracranial disease control confirmed in phase 1a for patients with brain metastases 160mg Baseline C3D1 CNS control in BM patien
Slide 49: Safety and tolerability outcomes in dose escalation
Investor Relations 2026 Safety and tolerability outcomes in dose escalation Favorable safety profile confirmed across all dose cohorts to date TRAE, n (%) All G≥3 VRN101099 (N=35) Any 19 (54) 2 (6) ✓ Overall, the safety profile was tolerable and manageable across all dose levels. Nausea 8 (23) 0 (0)
Slide 50: Phase 1 clinical trial design
Investor Relations 2026 Phase 1 clinical trial design Ongoing global phase 1 trial in South Korea and Australia, with first patient dosed in Q1 2025 Monotherapy trial and combination therapy trial is planned in phase 1b onward Phase 1a Highlights Phase 1 clinical trial design Key Eligibility Criteri
Slide 51: Thank You
Creating Novel Therapeutics For patients with Excellent Experts In Drug Design Thank You